1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
671BBE27B4FDFAFE785256E6A0057DD52
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/driving-pharma-rd-quality-excellence-key-findings-top-challenges-and-lessons-learned?opendocument
18
19opendocument
2044.220.247.152
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Quality, Compliance and Regulatory » Assuring Quality Programs

Driving Pharma R&D Quality Excellence: Key Findings, Top Challenges and Lessons Learned

DB Image

ID: 4594


Features:

Summary Matrix


Pages/Slides: 7


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

Leading pharmaceutical companies seek to achieve and maintain world-class excellence in all aspects of pharmaceutical quality from research and development to manufacturing. In pursuit of this goal, savvy companies aggressively seek the necessary information, insights and advice to advance the entire quality organization.

Key Findings
This seven-page document gives an overview of the key findings, top three lessons learned and the top three challenges in managing R&D quality excellence as identified by eight leading pharmaceutical companies.

Top findings include:
1. Companies with a centralized structure for R&D quality enjoy considerable staffing efficiency when compared to other organizational structures.
2. Almost all executives indicated that R&D Quality is not adequately staffed.
3. All partners identified the responsibility for auditing quality at thousands of clinical trial sites with limited staff as a tremendous challenge.

Methodology
This research originates from a Best Practices, LLC consulting project.


Industries Profiled:
Pharmaceutical; Biotech; Health Care; Medical Device


Companies Profiled:
Bristol-Myers Squibb; Sanofi-aventis; Abbott Laboratories; Amgen; Boehringer-Ingelheim; Cardinal Health; Eli Lilly; GlaxoSmithKline; Johnson & Johnson; Mayne; Medarex

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.